Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. (KTTAW) reported an officer departure on May 4, 2026, triggering a red-flag 8-K filing that warrants scrutiny into timing, replacement plans, and any underlying operational concerns. No cyber incidents were detected in our 90-day monitoring window, though the departure alone raises questions about management stability in a clinical-stage biotech environment. Our full $49 Report contextualizes this departure against the company's financing history, dilution risk score, equity structure, and any AI-detected patterns in SEC filings that might signal broader governance or cash-burn risks. The full $49 Report adds 12-month historical context, detailed dilution analysis, and our proprietary risk signals to help you assess whether this departure reflects routine turnover or material operational stress.